Greenwich LifeSciences, Inc. (GLSI) Financial Statements
Industry: Pharmaceutical Preparations
Net income was -$19.4M, or -$1.43 per diluted share. Operating activities generated -$9.9M of cash. At fiscal year end, Greenwich LifeSciences held $6.2M in total assets against $5.8M in total liabilities, including $6.2M of cash and equivalents.
Open the full interactive Greenwich LifeSciences financials → Quarterly statements, key ratios, valuation history and price charts.
Greenwich LifeSciences Key Stats
| Share Price | $15.50 |
|---|---|
| Market Cap | $226.6M |
| 52-Week Range | $7.85 – $33.56 |
| Shares Outstanding | 14.6 million (basic, 2026 Q2) |
Greenwich LifeSciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Operating Income | -$1.9M | -$4.6M | -$8.0M | -$9.3M | -$16.0M | -$19.4M |
| Pre-Tax Income | -$1.9M | -$4.6M | -$7.8M | -$8.9M | -$15.8M | -$19.4M |
| Net Income | -$1.9M | -$4.6M | -$7.8M | -$8.9M | -$15.8M | -$19.4M |
| Diluted EPS | -$0.20 | -$0.35 | — | -$0.69 | -$1.21 | -$1.43 |
Greenwich LifeSciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Net Income | -$4.2M | -$7.9M | -$5.7M | -$3.9M |
| Diluted EPS | -$0.30 | -$0.59 | -$0.39 | -$0.27 |
Greenwich LifeSciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $28.7M | $27.2M | $13.5M | $7.0M | $4.1M | $6.2M |
| Current Assets | $28.7M | — | — | — | — | $6.2M |
| Total Assets | $28.7M | $27.2M | $13.5M | $7.0M | $4.1M | $6.2M |
| Current Liabilities | $1.0M | $385,172 | $262,905 | $294,406 | $1.6M | $5.8M |
| Total Liabilities | $1.0M | $385,172 | $262,905 | $294,406 | $1.6M | $5.8M |
| Shareholders' Equity | $27.6M | $26.8M | $13.2M | $6.7M | $2.5M | $353,217 |
Greenwich LifeSciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$1.2M | -$4.3M | -$6.2M | -$6.5M | -$7.3M | -$9.9M |
| Cash From Financing | $29.8M | $2.8M | -$7.5M | — | $4.4M | $12.0M |
Figures from Greenwich LifeSciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Greenwich LifeSciences financials page for every line item.
Greenwich LifeSciences Company Profile
| Ticker | GLSI |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Stafford, Texas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001799788 |
Frequently Asked Questions
What was Greenwich LifeSciences' net income in fiscal 2025?
Greenwich LifeSciences reported net income of -$19.4M for fiscal 2025.
What was Greenwich LifeSciences' earnings per share (EPS) in fiscal 2025?
Greenwich LifeSciences' diluted EPS was -$1.43 for fiscal 2025 (adjusted for any later stock splits).
How many shares of Greenwich LifeSciences are outstanding?
Greenwich LifeSciences reported a weighted average of 14.6 million basic shares outstanding in 2026 Q2.
What is Greenwich LifeSciences' market cap?
Based on its latest closing price, Greenwich LifeSciences (GLSI) has a market capitalization of about $226.6M.
When does Greenwich LifeSciences' fiscal year end?
Greenwich LifeSciences' fiscal year end, as registered with the SEC, is December 31.
Where is Greenwich LifeSciences headquartered?
Greenwich LifeSciences lists its business address in Stafford, Texas in its SEC filings.